Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 4/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.35 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.35 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138964 | 0.82 | ALDH1A1 (0.33) | PDPK1KDRRETTLK2MAPT | |
| SCHEMBL7134014 | 0.77 | RET (0.48) | RETRAF1NPC1MAPTKMT2A | |
| SCHEMBL5377025 | 0.77 | RET (0.54) | KDRRETRAF1NPC1MAPT | |
| SCHEMBL7139913 | 0.76 | RAF1 (0.42) | RETRAF1MAPTKMT2ATDP1 | |
| SCHEMBL7137544 | 0.76 | LRRK2 (0.49) | RETRAF1MAPTKMT2ATDP1 | |
| SCHEMBL7138309 | 0.75 | MEN1 (0.51) | PDPK1KDRRETGSK3BMAPT | |
| SCHEMBL7139244 | 0.75 | MEN1 (0.51) | PDPK1KDRRETGSK3BMAPT | |
| SCHEMBL5366277 | 0.75 | RET (0.64) | PDPK1KDRRETTLK2NPC1 | |
| SCHEMBL7138976 | 0.75 | POLB (0.41) | PDPK1KDRRETRAF1MAPT | |
| SCHEMBL7136800 | 0.75 | MAP1LC3B (0.56) | RAF1MAPTKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PDPK1 31/4885KDR 239/4885RET 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.